$1.72
3.61% today
Nasdaq, Aug 12, 09:03 pm CET
ISIN
US45254U1016
Symbol
IMRN

Immuron Limited Sponsored ADR Stock price

$1.66
-0.08 4.60% 1M
-0.34 17.00% 6M
-0.04 2.35% YTD
-0.85 33.86% 1Y
-0.91 35.41% 3Y
-8.58 83.79% 5Y
+1.52 1,082.34% 10Y
+1.41 564.00% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.05 2.92%
ISIN
US45254U1016
Symbol
IMRN
Industry

Key metrics

Basic
Market capitalization
$11.9m
Enterprise Value
$6.8m
Net debt
positive
Cash
$5.0m
Shares outstanding
229.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.8 | 3.3
EV/Sales
1.6 | 1.2
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
81.7%
Return on Equity
-54.6%
ROCE
-62.1%
ROIC
-209.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.3m | $3.7m
EBITDA
- | -
EBIT
$-4.2m | -
Net Income
$-4.8m | $-150.0k
Free Cash Flow
$-5.1m
Growth (TTM | estimate)
Revenue
82.8% | 15.0%
EBITDA
- | -
EBIT
-125.7% | -
Net Income
-89.3% | 96.7%
Free Cash Flow
-118.3%
Margin (TTM | estimate)
Gross
67.5%
EBITDA
- | -
EBIT
-99.1%
Net
-112.4% | -4.2%
Free Cash Flow
-120.3%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
1.2%
Employees
7
Rev per Employee
$460.0k
Show more

Is Immuron Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Financial data from Immuron Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4.26 4.26
83% 83%
100%
- Direct Costs 1.39 1.39
209% 209%
33%
2.87 2.87
53% 53%
67%
- Selling and Administrative Expenses 5.06 5.06
41% 41%
119%
- Research and Development Expense 3.06 3.06
26% 26%
72%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -4.22 -4.22
126% 126%
-99%
Net Profit -4.79 -4.79
89% 89%
-112%

In millions USD.

Don't miss a Thing! We will send you all news about Immuron Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immuron Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
26 days ago
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia,...
Neutral
GlobeNewsWire
2 months ago
Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services University anticipates topline results of Travelan® clinical study in October 2025 Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025 Launch plans underway for ProIBS® in Australia Immuron anticipates IMM-986 (Vancomycin-resistant enterococci) ...
Neutral
GlobeNewsWire
4 months ago
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior year March 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter ...
More Immuron Limited Sponsored ADR News

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Head office Australia
CEO Mr. Lydeamore
Employees 7
Founded 1994
Website www.immuron.com.au

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today